Women have worse health-related quality of life and more activity limitations after stroke.
The FDA has expanded the treatment window for a clot retrieval device in certain patients presenting with acute ischemic stroke.
The results confirm that ischemic, hemorrhagic, and subarachnoid stroke have very different etiologies.
Although several studies have established the use of endovascular therapy with stent retrievers for selected acute stroke as standard of care, best practices surrounding the best sedation strategy remain unclear.
Under the new ischemic stroke guidelines, the treatment window for thrombectomy has been expanded to up to 24 hours after symptom onset.
A significantly shorter door-to-needle time is associated with the presence of a pharmacist at bedside during acute ischemic stroke.
Ginkgo biloba extract along with aspirin alleviates cognitive deficits in acute ischemic stroke.
Patients undergoing treatment for ischemic stroke are at greater risk for seizure development.
The effects of ischemic stroke on disability trajectories over an extended period of time were examined.
Patients enrolled in this study had strokes that were mild in severity, reducing the generalizability of these findings to the broader population.
Patients who experience acute coronary syndrome are at greater risk of recurrent ischemic events, including stroke.
All patients included in the study underwent a MRI or multimodal CT approximately 24 hours after onset of stroke.
Long-term, high-dose usage of PPIs increases the risk of first-time ischemic stroke and myocardial infarction.
Results from a secondary analysis of the ENCHANTED trial add to a pile of weak data that likely will not affect clinical practice.
Significant infarct progression can make patients ineligible for mechanical thrombectomy.
The findings support the continuation of high-intensity statin therapy after acute ischemic stroke.
Insulin-resistant patients with ischemic stroke or transient ischemic attack and a high risk of myocardial infarction or recurrent stroke are more likely to derive benefit from pioglitazone than those a lower risk.
A better understanding of characteristics of cerebral lesions may help expedite treatment and improve functional outcomes.
The investigators noted that rivaroxaban was associated with significantly reduced length of hospital stay compared with warfarin.
The findings align with current guidelines to administer IV tPA regardless of whether or not a patient with ischemic stroke is set to undergo mechanical thrombectomy.
There is some evidence that suggests intravenous thrombolysis for stroke may impair the blood-brain barrier and cause cerebral edema.
The findings may be less applicable to low-volume stroke centers who have less experience in this treatment.
Investigators found a positive association between higher childhood BMI scores and early adult ischemic stroke.
THRIVE scores not only accurately predicted good and poor outcomes in stroke patients following IVT or ET, but also the degree of ischemia following these treatments.
Despite disappointing results, tenecteplase's story in stroke treatment might not be over.
Women and patients of African-American race face an increased risk of experiencing poststroke recrudescence.
Only 16% of patients had an adequate response to conventional therapy, with patients who didn't considered "non-responders."
There are a limited number of prediction models that identify patients at risk of major bleeding after stroke or TIA.
Reduced door-to-needle times have been shown to improve outcomes after stroke.
Risk for symptomatic intracranial hemorrhage after endovascular treatment for acute ischemic stroke is significantly higher in real-world practice than rates reported by clinical trials.
Neurology Advisor Articles
- FDA Approves Blood Test to Assess Concussion
- Shortcomings in ALS Research: Strategies for Improvement
- Comparing Reference Points for Deep Brain Stimulation Location in Parkinson Disease
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease
- FDA Approves Clinical Decision Support Tool for Stroke
- Arimoclomol Shows Promise for Treating Rapidly Progressive SOD1 ALS
- CNS Abnormalities Common in Erdheim-Chester Disease
- Trial of Verubecestat for Prodromal Alzheimer Disease Discontinued
- Ischemic Stroke, Myocardial Infarction Both Tied to Lipoproteins, Lipids
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH